Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CAD | P27708 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9201482 | 1.00 | HTT (0.46) | HTTCADCYP2D6LMNABLM | |
| SCHEMBL8974020 | 1.00 | HTT (0.46) | HTTCADCYP2D6LMNABLM | |
| Trifluoroacetic Acid SCHEMBL31548889 | 0.89 | HTT (0.39) | HTTCAD | |
| SCHEMBL14286751 | 0.82 | HTT (0.33) | HTTCADKMT2A | |
| SCHEMBL10553644 | 0.80 | HTT (0.43) | HTTCADMAPTMAPK1ITGB3 | |
| SCHEMBL10101200 | 0.77 | KMT2A (0.53) | KMT2A | |
| SCHEMBL23370679 | 0.76 | ITGB3 (0.33) | LMNAKMT2AITGB3ITGB2ITGB1 | |
| SCHEMBL17169893 | 0.71 | HTT (0.46) | HTTCADCYP2D6LMNABLM | |
| SCHEMBL16467758 | 0.70 | CAD (0.48) | HTTCADCYP2D6LMNABLM | |
| Procysteine SCHEMBL9139321 | 0.70 | HTT (0.53) | HTTCADCYP2D6LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0298474-B1 | NOVEL CALCITONIN DERIVATIVE AND SALT THEREOF | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | claimed |
| US-5010174-A | Bone disorders, controlling calcium concentration in blood | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1991-04-23 | — | — | US | claimed |
| EP-0370165-A2 | Novel calcitonin derivative and salt thereof | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1990-05-30 | — | — | EP | claimed |
| EP-0298474-A2 | Novel calcitonin derivative and salt thereof | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1989-01-11 | — | — | EP | claimed |
| WO-2025094035-A1 | TOLL-LIKE RECEPTOR AGONISTS AND CONJUGATES THEREOF | PFIZER INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240000794-A1 | LACTAM AND LACTONE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION SUCH AS COVID-19 | Université Catholique de Louvain (BE) | 2024-01-04 | — | — | US | disclosed |
| WO-2022106646-A1 | LACTAM AND LACTONE DERIVATIVES OF FORMULA (IA) FOR USE IN THE TREATMENT OF DISEASES CAUSED BY A CORONAVIRUS INFECTION AND/OR A VIRAL RESPIRATORY INFECTION | Université Catholique de Louvain (BE) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106646-A1 | LACTAM AND LACTONE DERIVATIVES OF FORMULA (IA) FOR USE IN THE TREATMENT OF DISEASES CAUSED BY A CORONAVIRUS INFECTION AND/OR A VIRAL RESPIRATORY INFECTION | Université Catholique de Louvain (BE) | 2022-05-27 | — | — | WO | disclosed |
| EP-4000620-A1 | LACTAM AND LACTONE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION SUCH AS COVID-19 | Université catholique de Louvain (BE) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021093733-A1 | QUALITY CONTROL METHOD FOR CARBOCISTEINE RAW MATERIAL AND FORMULATION THEREOF, AND USE THEREOF | 广东华南药业集团有限公司 | 2021-05-20 | — | — | WO | disclosed |
| US-20120041194-A1 | NITROGEN AND SULFUR-CONTAINING HETROCYCLE DERIVATIVES | TRIAD MULTITECH PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041194-A1 | NITROGEN AND SULFUR-CONTAINING HETROCYCLE DERIVATIVES | TRIAD MULTITECH PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-5010174-A | Bone disorders, controlling calcium concentration in blood | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1991-04-23 | — | — | US | disclosed |
| EP-0304649-B1 | Salts of 6-piperidino-2,4-diaminopyrimidin-3-oxide and of derivatives of thiamorpholin-3-on-5-carboxylic acid, their cosmetical and medicinal use. | L'OREAL (FR) | 1991-03-20 | — | — | EP | disclosed |
| EP-0370165-A2 | Novel calcitonin derivative and salt thereof | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1990-05-30 | — | — | EP | disclosed |
| EP-0322779-A2 | Benzolactam compounds and pharmaceutical uses thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0304649-A1 | Salts of 6-piperidino-2,4-diaminopyrimidin-3-oxide and of derivatives of thiamorpholin-3-on-5-carboxylic acid, their cosmetical and medicinal use. | L'OREAL (FR) | 1989-03-01 | — | — | EP | disclosed |
| EP-0298474-A2 | Novel calcitonin derivative and salt thereof | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1989-01-11 | — | — | EP | disclosed |
| US-4100152-A | Peptides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-07-11 | — | — | US | disclosed |
| US-4045556-A | ANTIDEPRESSANTS, PYSCHOSTIMULANTS; SILYLATION | SCHWERTNER EBERHARD | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041194-A1 | NITROGEN AND SULFUR-CONTAINING HETROCYCLE DERIVATIVES | HRH4, HNMT, TST | HTT 22/4885CAD 3221/4885CYP2D6 1578/4885 |
| US-20240000794-A1 | LACTAM AND LACTONE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION SUCH AS COVID-19 | FURIN, SARS1, IL4I1 | HTT 3710/4885CAD 2652/4885CYP2D6 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.